Shares of Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) saw strong trading volume on Wednesday . 167,959 shares traded hands during trading, an increase of 17% from the previous session’s volume of 143,899 shares.The stock last traded at $9.00 and had previously closed at $9.32.

A number of equities analysts have issued reports on the company. Canaccord Genuity reiterated a “buy” rating and set a $22.00 target price on shares of Aquinox Pharmaceuticals in a report on Wednesday. Zacks Investment Research cut Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 9th. Needham & Company LLC assumed coverage on Aquinox Pharmaceuticals in a report on Thursday, May 12th. They set a “buy” rating and a $25.00 target price for the company. Finally, Jefferies Group increased their target price on Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the stock a “hold” rating in a report on Friday, August 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $19.86.

The company has a 50-day moving average price of $8.17 and a 200-day moving average price of $8.46. The firm’s market capitalization is $161.62 million.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its earnings results on Thursday, August 4th. The company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by $0.22. Analysts anticipate that Aquinox Pharmaceuticals Inc. will post ($2.08) earnings per share for the current year.

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.